Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Ovarian and fallopian tube disease".)
Canada
●Choosing Wisely Canada: Don't screen for ovarian cancer in asymptomatic women at average risk (2021)
United States
●National Cancer Institute (NCI): Ovarian, fallopian tube, and primary peritoneal cancer screening (PDQ) – Health professional version (updated 2023)
●ACOG: Committee opinion on hereditary cancer syndromes and risk assessment (2019, reaffirmed 2020)
●ACOG: Practice bulletin on hereditary breast and ovarian cancer syndrome (2017)
●ACR: Appropriateness Criteria on ovarian cancer screening (2017)
Europe
United Kingdom
India
Australia–New Zealand
●Cancer Australia: Position statement on testing for ovarian cancer in asymptomatic women (2019)
Japan
●[In Japanese] Choosing Wisely Japan: Screening tests for ovarian cancer – When necessary and not necessary (updated 2016)
Do you want to add Medilib to your home screen?